| 1. |
- Mantsinen, M. J., et al.
(author)
-
Fast ion distributions driven by polychromatic ICRF waves on JET
- 2005
-
In: Plasma Physics and Controlled Fusion. - : IOP Publishing. - 0741-3335 .- 1361-6587. ; 47:9, s. 1439-1457
-
Journal article (peer-reviewed)abstract
- Experiments have been carried out on the JET tokamak to investigate fast He-3 and hydrogen minority ion populations accelerated by ion cyclotron range of frequencies (ICRF) waves launched with multiple frequencies (i.e. up to four frequencies separated by up to approximate to 15%). This 'polychromatic' heating is compared with single-frequency, 'monochromatic', ICRF heating of reference discharges with similar power levels. Information on the fast ion populations is provided by two-dimensional gamma-ray emission tomography and the measurements are compared with numerical modelling. Polychromatic heating with resonances in the plasma centre (R-res approximate to R-0) and on the low magnetic-field side (LFS) (R-res > R-0) is found to produce predominantly high-energy standard trapped ions, while resonances on the high magnetic-field side (R-res < R-0) increase the fraction of high-energy passing ions. Monochromatic heating with a central resonance produces stronger gamma-ray emission with the maximum emission in the midplane close to, and on the LFS of, the resonance, in agreement with the calculated radial distribution of fast ion orbits. Both the fast ion tail temperature and energy content are found to be lower with polychromatic waves. Polychromatic ICRF heating has the advantage of producing smaller-amplitude and shorter-period sawteeth, consistent with a lower fast ion pressure inside the q = 1 surface, and higher ion to electron temperature ratios.
|
|
| 2. |
- Stephenson, I., et al.
(author)
-
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
- 2006
-
In: J Virol. ; 80:10, s. 4962-70
-
Journal article (peer-reviewed)abstract
- Trivalent influenza virus A/Duck/Singapore (H5N3), A/Panama (H3N2), and B/Guandong vaccine preparations were used in a randomized, controlled, dose-ranging phase I study. The vaccines were prepared from highly purified hemagglutinin and neuraminidase from influenza viruses propagated in embryonated chicken eggs and inactivated with formaldehyde. We assigned 100 participants to six vaccine groups, as follows. Three intranasally vaccinated groups received 7.5-microg doses of hemagglutinin from each virus strain with either 3, 10, or 30 microg of heat-labile Escherichia coli enterotoxin (LTK63) and 990 microg of a supramolecular biovector; one intranasally vaccinated group was given 7.5-microg doses of hemagglutinin with 30 microg of LTK63 without the biovector; and another intranasally vaccinated group received saline solution as a placebo. The final group received an intramuscular vaccine containing 15 microg hemagglutinin from each strain with MF59 adjuvant. The immunogenicity of two intranasal doses, delivered by syringe as drops into both nostrils with an interval of 1 week between, was compared with that of two inoculations by intramuscular delivery 3 weeks apart. The intramuscular and intranasal vaccine formulations were both immunogenic but stimulated different limbs of the immune system. The largest increase in circulating antibodies occurred in response to intramuscular vaccination; the largest mucosal immunoglobulin A (IgA) response occurred in response to mucosal vaccination. Current licensing criteria for influenza vaccines in the European Union were satisfied by serum hemagglutination inhibition responses to A/Panama and B/Guandong hemagglutinins given with MF59 adjuvant by injection and to B/Guandong hemagglutinin given intranasally with the highest dose of LTK63 and the biovector. Geometric mean serum antibody titers by hemagglutination inhibition and microneutralization were significantly higher for each virus strain at 3 and 6 weeks in recipients of the intramuscular vaccine than in recipients of the intranasal vaccine. The immunogenicity of the intranasally delivered experimental vaccine varied by influenza virus strain. Mucosal IgA responses to A/Duck/Singapore (H5N3), A/Panama (H3N2), and B/Guandong were highest in participants given 30 microg LTK63 with the biovector, occurring in 7/15 (47%; P=0.0103), 8/15 (53%; P=0.0362), and 14/15 (93%; P=0.0033) participants, respectively, compared to the placebo group. The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated.
|
|
